In contrast to most eukaryotic cells, neurons possess long, highly branched processes called axons and dendrites. In large mammals, such as humans, some axons reach lengths of over 1 m. These lengths pose a major challenge to the movement of proteins, vesicles, and organelles between presynaptic sites and cell bodies. To overcome this challenge axons and dendrites rely upon specialized transport machinery consisting of cytoskeletal motor proteins generating directed movements along cytoskeletal tracks. Not only are these transport systems crucial to maintain neuronal viability and differentiation, but considerable experimental evidence suggests that failure of axonal transport may play a role in the development or progression of neurological diseases such as Alzheimer's disease. 
INTRODUCTION
Effective communication between the cell bodies and presynaptic terminals of neurons requires reliable and timely movement of Axonal cargo: any molecule or organelle transported within axons essential neuronal "cargoes" to their final destinations. Such cargoes include vesicles containing synaptic proteins, growth factors, signaling molecules, and ion channels. In addition, defined organelles such as endosomes and mitochondria are continuously transported within axons. Finally, protein complexes including proteins controlling cytoplasmic signaling, structure, and degradation are also actively transported within axons. Whereas some of these cargoes reside in axons where they play structural and other roles, other cargoes participate in a variety of neuronal activities such as synaptic plasticity and neurotransmission. Recent findings implicate many such axonal cargoes in disease processes and suggest the existence of interplay between axonal transport, damage signaling, synaptic plasticity, and diseases of the nervous system.
The past decade has seen an explosion in our knowledge of molecules involved in axonal transport. At the same time, there has been a dramatic expansion in the identification of molecules that may cause diseases of the nervous system. Not only are these two sets of molecules beginning to overlap, but accumulating evidence suggests that many such disorders affect axonal transport during the course of disease, perhaps at the earliest or causative stages. Although such disorders may vary in their ages of onset, the anatomical substrates affected, and the clinical symptoms and signs produced, they may share failures of axonal transport, which may provide opportunities for common therapeutic interventions. Dendrites may also be prone to similar defects, but for a variety of technical reasons this possibility has not been as well explored. This review focuses on work in axons, recognizing that similar issues may pertain to dendrites as well.
dendrites were integral parts of neurons and neuronal circuits led to the suggestion that interruption between cell bodies and axons, and a resulting loss of trophic support, could account for the degeneration of fibers in the peripheral stump of a severed spinal nerve. This in turn led to the hypothesis that trophic material must be transported through axons to and from the cell bodies to maintain their structure and function.
Support for the proposal that active transport occurred in axons came from early studies of viral spread within neurons. Subsequent nerve constriction studies provided direct support for this hypothesis by demonstrating continuous transport of biological material along the axons (1) . An explosion of work eventually culminated in the demonstration of anterograde axonal transport by radiolabeling cargo proteins in axons and of retrograde axonal transport by studying the uptake of horseradish peroxidase. This work revealed not only the bidirectional nature of axonal transport, but also established that axonal cargoes travel at different velocities with fast axonal transport occurring at speeds of circa (ca.) 100-400 mm/day (ca. 1.0-5.0 μm/s) and slow axonal transport at speeds of ca. 0.3-3 mm/day (ca. 0.004-0.04 μm/s). The finding that microtubules are the major tracks or "highways" for long-distance axonal transport emerged from experiments where microtubule assembly was chemically disrupted, which resulted in abrogation of axonal transport and provided direct evidence for the involvement of microtubules (2) . Clues regarding the mechanism of such transport emerged from the determination of microtubule polarity, which in axons is highly organized so that microtubules have their plus ends oriented toward distal axons and presynaptic sites. These findings were soon followed by the identification of motor proteins that recognize microtubule polarity such as kinesin-1 and dynein, which transform chemical energy into mechanical movement toward microtubule plus and minus ends, respectively. 
Proteins Required for Axonal Transport
Microtubules serve as tracks along which motor proteins such as kinesins and dyneins generate long-distance transport. Microtubules are also decorated with microtubuleassociated proteins, which may modulate microtubule nucleation and elongation as well as control characteristics of motor protein transport. For example, there is compelling evidence that the tau protein, whose misbehavior is a prominent feature in many neurodegenerative disorders, can play a role in controlling motor protein-driven vesicle transport along microtubules (3) .
Compelling evidence suggests that motor proteins play a pivotal role in both fast and slow microtubule-based axonal transports. Microtubule plus end-directed or anterograde axonal transport is thought to rely largely on the kinesin superfamily of motor proteins, which are currently divided into 14 families based on their sequence similarities (4) . Strong evidence suggests members of the kinesin-1 (KIF5), -2 (KIF3), -3 (KIF1), -4 (KIF4), and -13 (KIF2) families participate in axonal transport; among them, kinesin-1 is the best studied. Structurally, kinesin-1 is a heterotetramer composed of two kinesin heavy chain (KHC) and two kinesin light chain (KLC) subunits (Figure 1) . KHCs (KIF5A, KIF5B, and KIF5C) contain microtubule-and nucleotide-binding sites in their NH2-terminal motor heads, alpha-helical coiled-coil stalks in the center, and globular COOH termini that interact with KLC and perhaps with cargoes. KLCs (KLC1, KLC2, and KLC3) contain NH2-terminal heptad repeat regions, which probably form alpha-helical coiled coils and mediate interactions with KHC. KLCs also contain COOH-terminal tetratrico peptide repeats that appear to be involved in cargo binding and in the regulation of transport. KIF5B and KLC2 are ubiquitously expressed; KIF5A and KIF5C are restricted in expression to brain and other neuronal tissue; and KLC1 (Figure 1) . Dynein heavy chains harbor microtubule-and nucleotide-binding sites within large COOH-terminal motor heads and NH2-terminal stemlike coiled coils. Dynein intermediate chains contain β-propeller group protein sequences and participate in the interaction with dynein heavy chains, dynein light chains, the dynactin complex, and perhaps cargoes. Dynein light intermediate chains and dynein light chains (Tctex1/rp3, roadblock, LC8) are thought to play a role in dynein-dynein and dyneincargo interactions via ATP-binding loop motifs and amphiphilic alpha-helical segments, respectively. Dynein-mediated axonal transport is thought to be regulated by its interaction with the dynactin complex, which consists of several proteins including p150Glued, p62, p50-dynamitin, the actin-related protein Arp1, actin, actin capping protein α and β subunits, p27, p25, and p24. Although many details remain to be elucidated, in vivo and in vitro studies suggest that disruption of the dynein/dynactin complex results in a striking axonal phenotype (9, 10) .
DHC

Mechanisms of Axonal Transport
Considerable effort has gone into elucidating the mechanisms by which motor proteins generate force and movement along microtubules (11, 12) . There are, however, two principles of motor protein mechanism that may play major roles in axonal transport biology. The first principle relates to the processivity of individual molecular motor proteins. A large body of evidence suggests that for highly processive motor proteins such as kinesin-1, the number of motor proteins on a moving cargo does not change the velocity of movement but does change the probability of pausing or stalling during transport (13) . In contrast, for poorly processive motor proteins such as dynein, motor number has a large influence on velocity as well as on the probability of pausing or stalling. Thus one expects the regulation of kinesin-1 or dynein motor number on moving cargoes to have different effects on the properties of flux and transport in axons. For example, decreasing kinesin-1 is predicted to change pause frequencies or perhaps the balance of anterograde and retrograde transport, but not velocity. This prediction has been experimentally observed (14) . The second principle relates to the question of whether single-headed motor proteins can generate force and movement. For example, kinesin-1 consists of two KHCs and contains two identical motor domains. Because its motor heads are interconnected by a coiled-coil stalk, they cooperate in a coordinated manner to achieve efficient processive movement along microtubules. In contrast, KIF1A lacks an extended predicted coiled-coil stalk domain and appears to be monomeric in its native state. Although researchers have proposed that KIF1A is capable of processive movement in its monomeric state by exchanging its microtubule-binding loops in a cyclic interaction with microtubules during each ATP cycle (15) , mounting evidence suggests that, to be efficiently processive, KIF1A monomers undergo a cargo-mediated transition to homodimers that move by a mechanism akin to that proposed for kinesin-1 (16, 17) . Thus, cargo interaction may activate some motor proteins by stimulating multimerization needed for processive movement.
Most cargo transport in axons may be generated by motor proteins attaching to vesicles, organelles, or protein complexes and mediating movement along stationary microtubules. However, at least two additional mechanisms of motor protein-generated, microtubuledependent axonal transport have been suggested to generate the array of movements observed. One mechanism may use stationary motor proteins attached to nonmotile axonal membranes to produce directed movement of microtubules and associated cargoes. In this mechanism, plus end-directed movement of microtubules and bound cargoes can be generated by minus end-directed motor proteins, and minus end-directed movements can be generated by plus end-directed motor proteins (18, 19) . Another mechanism derives from the observation that some motor proteins can attach simultaneously to two independent microtubules. In this case, plus end-directed motor activity between parallel microtubules will generate plus end-directed movements; minus end-directed movements could be generated by a minus end-directed motor activity (20) . In addition to the variety of data supporting these proposed mechanisms, considerable evidence suggests that in vivo several kinesin and dyneins work cooperatively to achieve cargo movement (21) . How these cooperative interactions fit into the overall geometry of force generation in axons remains to be elucidated. Finally, several relatively recent observations suggest that "fast" motor proteins such as kinesin-1 may be responsible for slow axonal transport. Genetic manipulation of kinesin-1 subunits revealed that removal of a specific KHC subunit called KIF5A produced defective transport of neurofilaments, which are known to be transported by slow axonal transport (5) . Indeed, in vivo imaging of neurofilament movement revealed these "slow" cargoes can travel intermittently at fast rates, but with slow average velocities owing to prolonged pauses and bidirectionality of movement (22) .
Regulation of Axonal Transport
Regulation of kinesin and dynein activities and thus regulation of axonal transport remain poorly understood. In principle, regulation can occur at one of several steps including cargo recognition and binding by the motor protein, velocity and character of transport itself, and recognition of the correct destination by the motor-cargo complex. Indeed, accumulating evidence suggests that kinesin-1 may be regulated directly by cargo binding such that motor activation is coupled to the binding of the motor to vesicles and/or organelles (23) (24) (25) . Similarly, as described above, at least one class of kinesin motor proteins may be activated by the clustering of phosopholipids, which facilitate dimerization required for processive movement (16) .
Among the many cargoes and binding partners identified for anterograde and retrograde motor proteins are several whose (26) and the group of c-Jun NH2-terminal kinase (JNK)-interacting proteins 1, 2, and 3 (JIP1, JIP2, and JIP3/Sunday driver) (27) . These proteins are directly connected to kinase and protease systems, among others. Additional evidence suggests important roles of phosphorylation in motor protein regulation, including perhaps the action of glycogen-synthase kinase 3β(GSK3β), presenilin-1 (PS1), and cyclindependent kinase 5.
AXONAL TRANSPORT, AGING, AND DISEASE
Many lines of evidence raise the possibility that failures in axonal transport play a role in a variety of neurodegenerative diseases. This evidence comes from study of the transport machinery during aging, reports of a variety of axonal defects that could be caused by transport problems in a number of neurodegenerative disorders, the realization that many proteins implicated in disease are actively transported, and the demonstration that some neurodegenerative diseases can be caused by mutations in genes encoding likely components or regulators of the transport machinery. In the case of Alzheimer's disease (AD), new evidence is emerging that links proteins implicated in disease causation to axonal transport. In all of these cases, it remains unclear where in the timing of disease progression transport failures emerge and what role such failures play in progression versus causation. We review this evidence below beginning with aging and diverse neurological diseases and ending with a discussion of these issues in the context of AD.
Axonal Transport and Aging
Aging has become an an intensely studied issue as a result of the increased prevalence of people reaching advanced age and the resulting increase in the incidence of diseases related to advanced age such as atherosclerosis and AD. Surprisingly, however, relatively little is known about how axons and axonal transport perform during aging and whether such changes might predispose some people to the development of aging-related diseases such as AD. Most studies thus far have examined the effects of aging either on axonal compartment structure or on axonal transport rates. Several studies reported age-related reduction in axonal microtubules (28) , shifts in the distribution of microtubule-associated proteins such as tau and neurofilaments (29, 30) , and the appearance of axonal accumulations of proteins such as APP (31) and other materials such as glycogen and lipofuscins. Perhaps the most obvious and direct evidence for age-related changes within axons is provided by the observation of progressive increases in the number of focal axonal swellings with age (32). These are reminiscent of similar agerelated accumulations of APP (31) . Intriguingly, some of these changes resemble those found in the Klotho mice, which recapitulate several characteristics of premature aging (33) . The substantial structural changes seen in axons with aging may hamper efficient axonal transport. This view is consistent with a number of radiolabeling experiments, which showed significant reductions in anterograde transport of axonal vesicles, various proteins, phospholipids, and steroid hormones. Reductions in the retrograde axonal transport of axonal vesicles, neurotransmitter-related proteins, growth factors, and steroid hormones and in the slow axonal transport of tubulin, neurofilaments, and synuclein have also been reported. The mechanisms underlying these age-related changes in axonal structure and transport remain obscure. In particular, it remains unknown whether these changes affect all transported proteins uniformly and thus might be a result of changes in the microtubule tracks or, alternatively, whether aging primarily affects only certain pathways (34) while sparing others.
Impairments in Axonal Transport and the Pathogenesis of Neurodegenerative Diseases
A number of neurodegenerative disorders appear to be caused by genetic defects in genes encoding proteins that play a direct role in axons and axonal transport. For example, Charcot-Marie-Tooth disease type II has been linked to mutations in genes encoding KIF1β (35) and the low molecular weight neurofilament protein (36) . Similarly, mutations in the KIF5A gene are found in hereditary spastic paraplegia (37) , and mutations in the p150
Glued gene are found in amyotrophic lateral sclerosis (ALS) (38) and distal spinal bulbar muscular atrophy (39) . These data corroborate results from studies with spastin (40), which support the hypothesis that impaired axonal transport could play a major role in the pathogenesis of hereditary spastic paraplegia. In addition, the identification of mutant p150
Glued as a cause of ALS adds genetic support to the reported axonal defects and impairments in axonal transport in the pathogenesis of ALS. Intriguingly, dynein mutations can suppress ALS caused by mutant SOD in mice (41) .
Genetic and cell biological evidence also implicate defective axonal transport in the pathogenesis of movement disorders such as Huntington's disease (HD). Although the expansion of CAG repeats in the gene encoding huntingtin is well established as the cause of HD, the mechanism(s) causing neurodegeneration and neurological defects remain(s) unknown. Some insights have emerged from reports that implicate the huntingtin protein in normal functions of the transport machinery. These findings are intriguing in light of reports suggesting that mutant huntingtin, and polyglutamine proteins in general, can cause impaired axonal transport and induce the formation of axonal protein aggregates in squid (42) , fruit fly (43) , and mammalian (44) HD. These observations together can account for the overt synaptic and axonal pathology in HD. Whether such a mechanism can acDementia: progressive decline in two or more cognitive functions that does not perturb consciousness, significantly affects independent everyday living, and is not caused by other known illnesses count for the preferential death of some cell types in HD as well as defects seen in other polyglutamine diseases remains to be seen. At least some of the ataxin genes encode proteins whose normal functions are nuclear, suggesting nuclear pathology may be primary in at least some of these disorders. Compelling experimental evidence in mouse models of spinocerebellar ataxia type 1 (45) supports this view. Comparable phenomena may be part of the pathogenesis of at least one form of early onset dystonia. Intriguingly, in the case of early onset dystonia linked to mutations in the AAA + protein torsin A, a pathogenic mutation that encodes a mutant torsin A lacking a glutamic acid residue in the COOH termini has been reported to interrupt the binding of torsin A to KLC1 and result in its deficient transport (46) .
With respect to the pathogenesis of some of the major dementias, a genetic association between abnormalities in the tau gene and some forms of fronto-temporal dementias, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy is well established (47) and consistent with the proposal that defective tau function may cause defects in the assembly and stability of microtubules in turn leading to defective axonal transport. Similar changes in tau biology can cause abnormal axonal transport in cell culture including defective peroxisomal transport, perhaps leading to sensitivity to oxidative damage (3). Transport defects are also seen in tau animal models (48) , although the precise mechanisms remain unknown. Intriguingly, abnormalities in tau protein are found diffusely in AD and represent one of its pathological hallmarks. Although the genetic associations between tau and AD are tentative, the biological roles of tau suggest that cytoskeletal defects and failed axonal transport can contribute to the pathogenesis of common dementias.
In summary, genetic and functional studies provide strong evidence for the involvement of impaired axonal transport in the pathogenesis of several neurodegenerative disorders.
DAI: diffuse axonal injury
TBI: traumatic brain injury
Aβ: amyloid-β peptide
Whether other disorders such as KIF21 defects in congenital fibrosis of the extraocular muscles type 1 and defects in KIF13 linked to schizophrenia have similar origins remains to be determined.
Impaired Axonal Transport as a Result of Diseases
Although axonal transport is not obviously causally related to the onset of many diseases of the nervous system, these diseases appear to affect, perhaps indirectly and significantly, axonal structure and transport. Understanding the mechanisms underlying axonal insult in these diseases may provide valuable clues for the development of new diagnostic assays and therapeutics. Examples of diseases where significant advances in understanding the mechanisms of axonal injury have been achieved are diffuse axonal injury (DAI) and demyelinating diseases.
DAI is a consequence of traumatic brain injury (TBI) and an epigenetic risk factor for AD. In DAI, a massive accumulation of APP and its potentially toxic proteolytic product, amyloid-β peptide (Aβ), takes place within swollen axons at injury sites. This finding is intriguing given the strong evidence that APP contributes to the pathogenesis of AD and that TBI is a risk factor for AD. Recent work suggests that impaired axonal transport as a result of TBI (49) can cause long-lasting accumulations of APP, its proteolytic machinery, and kinesin-1 within axonal swellings that contain intra-axonal Aβ. Release of axonally generated Aβ into the extracellular space may contribute to amyloid deposition in DAI.
Researchers have also proposed that axonal damage and loss may be responsible for the persistent neurological deficits observed in patients with demyelinating diseases such as multiple sclerosis and acute disseminated encephalomyelitis. APP accumulation within damaged axons also occurs in demyelinating diseases (50) . Nevertheless, little is known about the mechanism by which axonal segments adjacent to compromised oligodendrocytes incur injury. Whereas an autoimmune destruction of the myelin sheaths surrounding axons and compromised conduction properties of the denuded axons are widely accepted, recent studies offer new insights into the mechanisms responsible for the accompanying axonal defects. Although the mechanisms remain to be clarified, these studies show that oligodendrocytes deficient in the myelin proteolipid protein (51) as well as activated microglia (52) can both cause impaired fast axonal transport.
That APP and Aβ accumulate within damaged axons in several diseases suggests that APP may represent a surrogate marker of axonal pathology. Thus APP and/or Aβ may be susceptible to reductions in axonal transport or play a general role in axonal repair or regeneration. Intriguingly, studies of NiemannPick type C disease provide another link between impaired axonal transport, axonal defects, and Aβ generation. In brief, Niemann-Pick disease type C is characterized by intracellular accumulation of unesterified cholesterol within the endocytic pathway, endosomal abnormalities, and well-described axonal defects. Coincidently, experimental models of Niemann-Pick disease type C exhibit impaired axonal transport of endogenously synthesized cholesterol, accumulations of APP and PS1, and aberrant generation of Aβ (53, 54) . These studies support the view that deficient transport can play an important role in the generation of Aβ and are consistent with the findings from DAI studies.
AXONAL TRANSPORT AND ALZHEIMER'S DISEASE
That the observed pathological changes in AD are at least partly the result of abnormal axonal transport has been discussed for decades (55) . However, until recently, too little was known about the axonal transport machinery to critically test these ideas. Here we summarize the major features of AD, the axonal transport and functions of AD-related molecules, and axonal defects seen in AD. We then discuss how a cascade of axonal blockages could cause the pathogenesis of AD.
Overview of Alzheimer's Disease
AD was first described in a report that associated bizarre psychiatric symptomatology with the postmortem observation of senile plaques and neurofibrillary tangles. Senile plaques were later described to consist of a network of dystrophic neurites embedded in extracellular, congophilic, and fibrillar amyloid (56) . These neuritic changes and amyloid deposits are commonly accompanied by a prominent glial reaction. At about the same time neurofibrillary tangles were found to correspond to intracellular accumulations of paired helical filaments (57) . AD is the most common dementia with senile plaques and neurofibrillary tangles as pathological hallmarks when found in diagnostically relevant brain regions (58, 59 ). In addition, AD brains generally exhibit severe perturbations of several neurotransmitters and widespread synaptic and neuronal loss in distinct anatomic areas such as the limbic system and the basal forebrain (60) (61) (62) (63) . These changes are accompanied by a severe disruption of the axonal as well as dendritic cytoskeleton, which suggests failed axonal transport at some point in the progression of the disease.
To date, mutations in three independent genes have been found to segregate with kindreds afflicted by rare familial AD (FAD). The first gene emerged from studies focused on the purification and sequencing of proteins found in amyloid deposits (64) . These studies identified Aβ as the major constituent of amyloid, which led to the identification of the precursor protein, APP (65) (66) (67) . A number of mutations in the human gene-encoding APP were found to cause some forms of FAD, perhaps as a result of aberrant Aβ genera- (69, 70) . In addition, the mapping of APP to chromosome 21, which is trisomic in Down's syndrome, provided a possible cause for the AD pathology consistently observed in the brains of Down's syndrome patients. Further genetic studies identified mutations in PS1 and presenilin-2 (PS2) as additional genetic causes of FAD (71) . The finding that mutations in PS1 and PS2 also lead to aberrant Aβ generation was an important clue for deciphering the mechanism of Aβ formation and led to the discovery that presenilins are likely key components of the proteolytic processing machinery for APP and other proteins such as Notch (72) . In fact, a combination of results from many studies revealed that Aβ formation can be either abrogated or stimulated by the proteolytic processing of APP. Cleavage of APP within the Aβ domain of APP (α-cleavage) abrogates Aβ formation, whereas sequential cleavage of APP at the N termini (β-cleavage) and C termini (γ-cleavage) of the Aβ domain of APP results in Aβ formation (Figure 2) (65, 73) . Members of the disintegrin and metalloproteinase families were identified as participants in the α-cleavage, and the β-site APP cleaving enzyme (BACE) as a participant in the β-cleavage, whereas nicastrin, anterior-pharynx defective protein-1 and presenilin enhancer-2, along with PS1, orchestrate the γ-cleavage of APP. Finally, apolipoprotein ε4 alleles were found to be associated with earlier onset and more aggressive forms of AD. These findings, together with the discovery that abnormally hyperphosphorylated tau forms the neurofibrillary tangles (74), provide a framework for understanding the molecular basis of AD.
The genetic and biochemical data, combined with the observation that amyloid plaques are a characteristic feature of AD, led to the formulation of the amyloid-cascade hypothesis (75) (76) (77) . In its simplest form this hypothesis suggests AD develops as a result of either increased production of Aβ throughout life owing to FAD mutations or owing to a gradually increasing buildup of Aβ as a result of failed mechanisms of Aβ clearance thought to occur in sporadic AD cases. These events are proposed to result in accumulation, oligomerization, and deposition of Aβ. Aβ oligomers or deposits are thought to activate microglia, trigger an inflammatory response, and alter synaptic structure or functions. These events might in turn give rise to altered neuronal homeostasis, altered kinase and phosphatase activities, the formation of neurofibrillary tangles, and widespread synaptic and neuronal dysfunction and loss precipitating in dementia.
Although there are clear causative relationships between genes controlling Aβ formation and AD, several features of AD are not well accounted for by the amyloid-cascade hypothesis. A major issue is the apparently poor correlation between amyloid deposits and other aspects of the pathology observed in AD brains (78) . For example, an obvious relationship between senile plaques and neurofibrillary tangles is lacking (79) . Whereas neurofibrillary tangles start forming in the entorhinal region and then spread toward the cortices, the opposite appears true for senile plaques (80, 81) . Similarly, synaptic numbers are generally not consistently affected by amyloid deposits in animal models of AD, and data establishing a role for Aβ in decimating synaptic and neuronal numbers in vivo are lacking. In addition, neuronal loss in AD often occurs independently and in anatomically distant regions from areas of amyloid deposition. Finally, amyloid burden is not well related to the clinical picture of AD. For example, significant amounts of amyloid can be found deposited in the brains of cognitively intact subjects (82) . Amyloid burden in AD brains is variable and does not predict either the duration or severity of AD. Furthermore, many of the symptoms observed in AD result from damage to brain areas often devoid of amyloid deposits.
Axonal Transport of Proteins Linked to the Pathogenesis of Alzheimer's Disease
Many proteins associated with the pathogenesis of AD (including APP, BACE, PS1, nicastrin, Aph-1, presenilin enhancer-2, synuclein, and tau) have been observed in the axonal compartment of neurons, with many of them found at presynaptic terminals (83) (84) (85) (86) . Thus, transport is almost certainly necessary to deliver these proteins to their final destinations (87) . For APP, there is strong evidence from cell culture, Drosophila, and mice that kinesin-1 is responsible for APP transport (26, (88) (89) (90) . There are also reports that PS1, BACE, and synuclein undergo axonal transport at speeds consistent with fast anterograde axonal transport (91) (92) (93) (94) (95) , and although there is some controversy (96) , APP, BACE, and PS1 have been suggested to travel within the same membrane compartment in axons (92, (97) (98) (99) (100) . Some proposals for the mechanism of APP transport suggest the C terminus of APP interacts with the tetratrico repeats of the kinesin-1 KLCs (26), either directly, but possibly enhanced by JIP1 (101), or indirectly via complex formation with JIP1 (96, 102) . Intriguingly, APP has also been reported to undergo fast anterograde axonal transport as a component of the herpes simplex virusderived viral particles associated with kinesin-1 (103) . Further work is required to better understand the mode of interaction between APP and KLCs; to evaluate the mechanisms of axonal transport of BACE, PS1, and other molecules involved in AD; and to identify additional partners, such as proteins interacting with APP tail 1 (104) , that might take part in transporting axonal APP. Interestingly, recent observations indicated that unlike JIP1 and JIP2, which associate and phosphorylate APP, JIP3 does not associate with APP but may play a role in regulating its transport and phosphorylation (105) .
Axonal Functions of Proteins Linked to the Pathogenesis of Alzheimer's Disease
Mounting evidence suggests that many proteins implicated in the pathogenesis of AD have functions in the axonal compartment. For example, early work on the biological functions of APP suggested a possible role in promoting axonal growth (106, 107) . In fact, several cell-culture studies suggested that reductions (108, 109) , overexpression (110) , and other modifications of APP (111) could cause abnormalities in axonal growth. Similarly, deletions (112, 113) or overexpression of APP (114, 115) in mice both gave rise to reductions in white-matter brain structures and corroborated cell-culture studies by providing in vivo evidence for a role of APP in the maintenance of axonal structure and function. These data are consistent with the observed upregulation and axonal enrichment of APP during nervous system development and in axonal injury states when molecules involved in axonal growth are expected to be most active (106, 116) . Of particular interest in this context are reports of axonal increases in APP in several disease states that exhibit axonal injury. These disease states include multiple sclerosis, TBI, brain infarctions and infections, and neurodegenerative diseases such as Creutzfeldt-Jakob's or AD. These observations therefore suggest APP may play an important role during axonal repair. This conjecture is supported by recent experiments in Drosophila indicating a role of the Drosophila APP-like (APPL) gene in recovery from brain injury (116) . APP accumulation within axons in disease states could also be the result of abnormal or continued axonal transport in the presence of axonal blockages.
Recent work in mice suggests that APP may play a role within the axonal compartment by participating in axonal transport (92, 117) . Although controversial (96) , this proposal is based on the initial observation that reduction or overexpression of APP in Drosophila (90, 118) causes axonal transport www.annualreviews.org • Axonal Transport and ADdeficits reminiscent of those observed in motor protein mutants (119) . Similar defects have been observed in mice overexpressing APP (120) and in AD (14) . Finally, axonal transport deficits caused by APP overexpression in Drosophila and mice can be enhanced by otherwise benign reductions of kinesin-1 (14, 90) . Consistent with these data are the findings that synapses in flies and mice deficient in APP exhibit reduced numbers of synaptic boutons (121) (122) (123) .
In addition to a role in APP processing, some evidence suggests that both PS1 and BACE possess additional functions within the axonal compartment. Similar to APP, manipulations of PS1 in cell-culture systems reveal a role in axonal growth and morphology (124) (125) (126) (127) , which has been shown to be important in development of the nervous system (126, 128) and in states of axonal injury (99) . Examination of the means by which PS1 exerts its functions in the axonal compartment suggests several mechanisms ranging from direct (126, 129) to indirect actions (130) on the axonal cytoskeleton. Intimate involvement in the control of the axonal transport machinery via phosphorylation of KLC by GSK3β (131, 132) may also occur. Intriguingly, PS1 may also control the transport of APP and other proteins, possibly via GSK3β (133, 134) . These ideas are consistent with a wealth of data that, although disputed (135) , suggest that APP and PS1 interact (136) (137) (138) (139) . Although less is known about BACE, its overexpression produces overt axonal degeneration (140) and results in reduced axonal transport of APP (141) . More specifically, BACE overexpression may shift β-cleavage of APP to the cell bodies, which results in inappropriate post-translational modifications of APP, in reduced targeting of APP into the axonal compartment, in reduced axonal transport of APP, and in diminished Aβ generation (141) . Intriguingly, tau has also been proposed to regulate kinesin-1-mediated vesicle and organelle transport along microtubules as well as organizing axonal microtubules. Related roles in axonal transport may unite tau-related and APP-related pathologies in AD, perhaps via interactions including JIP1 and GSK3β (3, 52, 142) . Such a view is consistent with the reported colocalization of APP, BACE, PS1, and Aβ in swollen axons induced by diffuse axonal injury (99) .
Axonal Defects and the Pathology of Alzheimer's Disease
Years of pathological examination of AD brains have yielded many descriptions of abnormal axons. These axonal defects may reflect transport problems and can be divided into three classes: (a) those juxtaposed to amyloid within senile plaques; (b) those associated with neurofibrillary tangles, and (c) those spatially distinct from the hallmark lesions of AD.
First, dystrophic axons juxtaposed to amyloid are the best studied and are found associated with dense amyloid cores as well as with smaller amyloid bundles. Some workers have proposed that these dystrophic axons are more specific to AD than the amyloid itself (143) . Some evidence suggests that amyloidassociated dystrophic neurites are best distinguished based on whether they harbor abnormally phosphorylated tau (144) . In fact, most such axons are immunoreactive to axonal cargo proteins such as synaptophysin or tau (144, 145) . In addition, a subpopulation of abnormal axons found adjacent to the amyloid was identified to accumulate actin, actin-depolymerizing factor, and cofilin (146) . Overall, the tight relationship between amyloid and abnormal axons indicates that either amyloid underlies the formation of axonal defects or that axonal defects represent "hot spots" implicated in the amyloid deposition or both.
Second, abnormal axons associated with neurofibrillary tangles in AD are well described (147) . Abnormal thin and tortuous axons immunoreactive to a battery of different phospho-tau epitopes represent an invariable feature of AD brains. These axons can be found in areas either spatially distinct from, or adjacent to, the amyloid deposits and neurofibrillary tangles. Although massive disorganization of the axonal compartment by the abnormally phosphorylated tau is associated with an abnormal microtubule network, it is unclear whether this can be accounted for by the action of abnormal tau (28) . Interestingly, evaluation of abnormal axons associated with neurofibrillary tangles suggests that at least some of these are not related to amyloid (148) . These tangle-associated neuritic clusters are enriched in tau and form dense aggregates and ghost tangles with the core made up of extracellular bundles of straight filaments. Although the significance of tangle-associated neuritic clusters in AD remains largely unexplored, the clusters provide important evidence that amyloid is not necessarily present in axonal defects at all stages and, alternatively, that amyloid is not required for the formation of some populations of abnormal axons encountered in AD brains.
Third, abnormal axons spatially distinct from the hallmark lesions of AD consist of shorter, more irregular, and tortuous processes (14, 149) . These are most evident as focal axonal swellings that correspond to abnormal accumulations of axonal cargos and transport proteins (14) . These swellings exhibit aberrant phosphorylation of neurofilaments but not of tau. They form early in AD and precede tau-immunoreactive axons spatially distinct from amyloid deposits and neurofibrillary tangles. Importantly, because abnormal axons form in brain areas that eventually develop hallmark lesions of AD, it is plausible they represent precursor lesions to those observed associated with amyloid and tangles.
Several studies reported axonal loss in brain regions typically afflicted by AD (150) and also in the olfactory and optic nerves, which are readily amenable to axonal quantification (151) (152) (153) . Similarly, in vivo imaging studies of brains from AD patients showed selective white-matter changes (154, 155) . These studies are consistent with the variety of axonal defects observed in AD brains and with the clinical disconnection syndrome demonstrated in subjects afflicted by AD (156) .
A number of animal models expressing AD-related proteins exhibit a variety of axonal defects akin to those observed in AD. Intriguingly, these defects were observed not only in models based on molecules tightly linked to AD such as tau, APP, BACE, or PS1 (14, 140, 157, 158) , but also in models based on molecules more distantly related to AD such as p25 and apolipoprotein ε4. In Drosophila, overexpression of APP alone or of APP and tau resulted in axonal defects reminiscent of those observed in Drosophila motor protein mutants (90, 118) . Comparison of dystrophic neurites juxtaposed to amyloid in AD brains with those in brains of mouse models of AD also revealed striking similarities (159) . Intriguingly, similar dystrophic axons could be found in areas devoid of amyloid or neurofibrillary tangles in AD (14) . Therefore the formation of axonal defects may not require the presence of amyloid-or tau-related changes although these pathologies may modify or enhance axonal abnormalities.
Impairments in Axonal Transport and the Pathogenesis of Alzheimer's Disease
There is a considerable amount of data consistent with the hypothesis that impaired axonal transport plays a crucial role in the pathogenesis of AD (55) . These data include the consistent observation of widespread axonal pathology in AD including abnormal axons that exhibit aberrant accumulations of APP (160) and its metabolites (161, 162) ; synapse-(163), endocytosis-(164), and neurotransmitterrelated proteins (14, 165) ; resident axonal proteins such as neurofilaments and tau; glycogen (166) ; and organelles (167) , in addition to the sequestration of tubulin (168) ; reduced number of microtubules tracks (28) ; and the emergence of abnormal filaments (169) . These abnormal axons appear to comprise an important component of the dystrophic neurites www.annualreviews.org • Axonal Transport and ADthat constitute senile plaques and, therefore, correspond to an essential pathological component of AD. The observation that development of axonal abnormalities in some brain regions precedes the rest of known AD pathology, whereas in others it occurs in spatially distinct areas from the rest of the known AD pathology, together with the finding that abnormal axons form at least one year prior to amyloid deposition in some mouse models (14) , suggests the production of axonal defects could coincide with the earliest stages of AD pathogenesis. Intriguingly, reductions in kinesin-1 motor proteins promote the development of axonal defects in Drosophila (90, 118) . In mouse similar kinesin-1 reduction enhances the development of axonal defects, increases aberrant Aβ generation, and enhances amyloid deposition (14, 90) . These data suggest a causal relationship between failed axonal transport and the generation of axonal abnormalities and provide a direct link between changes in axonal transport, aberrant accumulation or production of Aβ, and the formation of senile plaques. Similarly, several studies showed that Aβ per se is sufficient to induce the formation of axonal abnormalities (170) and may directly contribute to the impairments in the axonal transport (171, 172) . Whether aberrant axonal Aβ generation causes failed axonal transport and axonal defects or whether aberrant Aβ generation might be the result of impaired axonal transport that causes further deterioration of axonal transport is unclear.
Abnormal phosphorylation of tau and the corresponding axonal abnormalities are an invariable feature of AD that may directly impair axonal transport of APP and other molecules (173) . This feature of AD is intriguing in light of reported improvements in axonal transport, increased numbers of microtubule tracks, and ameliorated motor impairments observed in tau transgenic mice upon treatment with microtubule-stabilizing drugs (174, 175) . Unexpectedly, some mutations linked to kindreds afflicted by FAD alter axonal transport of axonal cargoes including APP (131, 133) . This finding provides a link between abnormal processing of APP, aberrant Aβ generation, and impairments in axonal transport. Several risk factors for AD development including advanced age, apolipoprotein ε status, and repetitive trauma have all been linked to defects in axonal transport. For example, aging may be associated with reduced axonal transport in anatomically relevant areas to AD, such as in the basal cholinergic forebrain (176), whereas homozygosity for apolipoprotein ε4 produces white-matter changes in asymptomatic subjects (177) .
We find it striking that impairments in axonal transport present an economical explanation for the early synaptic changes observed in AD along with the observations that cortical levels of nerve growth factor in AD are normal even though basal forebrain cholinergic neurons exhibit features diagnostic of nerve growth factor deprivation (178, 179) . We also think it is relevant that cortical levels of cholinergic enzymes are reduced in AD even though basal forebrain cholinergic neurons retain normal expression of cholinergic markers for some time after disease onset (180) . The finding of significant reductions in axonal transport in postmortem AD brains (181) corroborates these observations as do the obvious changes in tau and other cytoskeletal proteins in axons.
We suggest that small initial changes in axonal transport pathways or spontaneously occurring axonal blockages over time can trigger early abnormalities in synaptic and axonal structure and function and the development of sporadic AD. Such impairments might be a consequence of age-related reductions in microtubule number or transport, oxidative stress (182), or perhaps traumatic brain injury. Impairment of axonal transport could stimulate Aβ generation (14) , which at some point cannot be efficiently cleared and starts accumulating. Abnormal accumulations in Aβ might induce further deterioration of axonal transport, more pronounced axonal pathology, and additional impairments in synaptic function. Importantly, impairments in axonal transport and aberrant Aβ generation could mutually potentiate each other in a vicious cycle, producing increasing damage over time including perhaps tau abnormalities. Such a vicious cycle, consisting of impaired axonal transport, aberrant Aβ generation, and tau abnormalities, might lead to the formation of paired helical filaments and clusters of axonal defects from multiple axons. This would mark the beginning of amyloid deposition and the appearance of neurofibrillary tangles. Notably, axonal blockages must also hamper retrograde axonal transport pathways (183) that provide cell bodies with the neurotrophic signals important for the maintenance of their differentiated state and survival (184) , which could result in neuronal loss.
In FAD, blockages might be initiated by abnormal processing or transport of APP and in Down's syndrome by abnormal levels of APP similar to that reported in Drosophila and in mouse (14, 90) . Finally, polymorphisms in the KLC1 subunit of kinesin-1 have been reported to increase the risk of AD (185) , although large-scale studies are required to confirm or refute those data.
Although we favor a mechanism in which defective axonal transport or age-related defects in axonal transport precipitate AD, we recognize that this hypothesis does not account for all features of this disease. For example, similar to the amyloid-cascade hypothesis, an axonal blockage cascade does not explain the regional selectivity of the damage observed in AD. In addition, it does not explain the apparent lack of peripheral nervous system involvement. Furthermore, no hypothesis proposed thus far provides a clear account of what triggers the development of the prevalent sporadic form of AD. Further work is required to test rigorously the mechanisms involved in the pathogenesis of AD and to critically examine whether axonal transport plays a definitive role in the causation or the progression of AD.
SUMMARY POINTS
1. Many proteins linked to the pathogenesis of neurodegenerative disorders including AD undergo axonal transport and may be important to maintain not only synaptic but also axonal structure and function.
2. Recent data suggest that impaired axonal transport can promote aberrant Aβ generation and enhance amyloid deposition. Thus, an intimate link between axonal transport and protein deposition in the pathogenesis of AD may exist.
3. Axonal defects are observed early in AD, and APP accumulates in damaged axons in several disease and injury states.
FUTURE ISSUES TO BE RESOLVED
1. How is axonal transport regulated and what is the basis for age-related changes in axonal transport?
2. Are defects in axonal transport a cause or a consequence of the pathological changes in AD?
3. Do genetic variations in AD susceptibility identify genes involved in axonal transport functions?
